Tele: 561.316.3330
Breaking Medical Device News

Monday, September 27, 2021
HomeIntersect ENTIntersect ENT Receives CE Mark Approval for PROPEL® Contour for Patients with Chronic Rhinosinusitis Following Frontal Sinus Surgery

Intersect ENT Receives CE Mark Approval for PROPEL® Contour for Patients with Chronic Rhinosinusitis Following Frontal Sinus Surgery

Intersect ENT®, Inc. (Nasdaq: XENT), a global ear, nose and throat (“ENT”) medical technology leader dedicated to transforming patient care, today announced it has received CE Mark approval for the company’s PROPEL® Contour (mometasone furoate) sinus implant enabling sales and distribution in the European Union.

The Contour CE approval expands the portfolio of PROPEL products available for commercialization inclusive of PROPEL and PROPEL Mini. PROPEL Contour is specifically designed to maintain patency and reduce inflammation, and conform to the sinus ostia (openings) by focusing mechanical support and steroid delivery where it is needed to optimize sinus surgery outcomes. It is the third localized drug delivery implant, completing the PROPEL family of drug-eluting, bioabsorable implants now available to ENT specialists in select EU countries.

PROPEL Contour features an innovative hourglass shape, specifically designed for placement in the frontal sinuses (between the eyebrows) following sinus surgery for chronic rhinosinusitis patients. The implant features a low-profile flexible delivery system to make it easier to access areas of the frontal sinus ostia.

“Having the ability to accommodate the size and variable shape of the frontal sinus openings with the PROPEL Contour sinus implant is a great advantage for ENT specialists who treat patients suffering from chronic rhinosinusitis,” said Prof. Dr. Jan Gosepath, Chairman, Department of Otolaryngology, Head and Neck Surgery, Helios HSK Wiesbaden and Medical Director, Helios Private Clinic Wiesbaden. “Since this bioabsorbable implant is designed to be self-retaining against the tissue lining, the surgically enlarged sinus opening can be maintained and the steroid can be delivered directly to the site where it is needed most to improve post-operative outcomes.”

Chronic rhinosinusitis is one of the most common chronic medical conditions worldwide, affecting all age groups, with an estimated incidence of nearly 11% in Europe. Of those in the UK with chronic sinusitis, approximately 15 percent undergo sinus surgery yearly after failing medical treatment. Quality of life scores of patients with chronic sinusitis are significantly lower than in other common chronic diseases, such as congestive heart failure, angina, chronic obstructive pulmonary disease, and back pain. Chronic sinusitis symptoms may include drainage of excess mucus, nasal blockage or congestion, difficulty breathing, pain and tenderness around the eyes, cheeks, nose, and forehead, a reduced sense of smell and taste, and fatigue and irritability.

“We are pleased that PROPEL Contour, the latest addition to the PROPEL family of steroid-releasing sinus implants, is now available in select EU countries to treat patients undergoing sinus surgeries, which represent the majority of procedures for the treatment of chronic rhinosinusitis,” said Thomas A. West, President and Chief Executive Officer of Intersect ENT. “Our goal is to offer sinus physicians the broadest range of products so they can customize treatment for each patient with focused drug delivery and mechanical support where it is needed to optimize sinus surgery outcomes. The introduction of Contour is consistent with our strategic growth initiatives, where we expect to see more significant revenue contributions from PROPEL and our other technology platforms across Europe over the coming years.”

The CE Mark approval was supported by positive data from the PROPEL Contour cohort of the US clinical study – PROGRESS, a prospective, randomized, blinded, multi-center trial of 80 patients designed to assess the safety and efficacy of the implant when placed in the frontal sinus ostia, following endoscopic sinus surgery (ESS) with traditional instrumentation, balloon dilation, or a combination of both.

The study met its primary efficacy endpoint, demonstrating a statistically significant 65 percent relative reduction in the need for post-operative interventions, such as the need for additional surgical procedures or the need for oral steroid prescription, compared to surgery alone + standard of care. There were no implant related serious adverse events reported in the clinical studies. The most common adverse reactions observed in > 2% of subjects were acute sinusitis, asthma, headache, chronic sinusitis, upper respiratory tract infection, fungal sinusitis, nasopharyngitis, nausea, neck pain, sinus headache and streptococcal pharyngitis.

Medical Device News Magazine
Medical Device News Magazine is a division of PTM Healthcare Marketing, Inc. Pauline T. Mayer is the managing editor.

Stay Connected


Don't Miss

Nanox to Announce Zebra Medical Vision Secures 8th 510K FDA Clearance for its Coronary Artery Calcium (CAC) Solution as Part of Its Population Health Offering

On August 10th, 2021 Nanox announced that it had entered into an acquisition agreement via merger with Zebra Medical Vision LTD.

Christopher Joyce Joins Miach Orthopaedics as VP & CFO

Christopher Joyce has joined as vice president and chief financial officer, and Kevin Sidow has been appointed to the company’s board of directors.

NGMedical GmbH Receives FDA Clearance for Its AM Titanium Lumbar Interbody BEE® PLIF

The BEE® PLIF cage has been created to benefit from additive manufacturing features. The purposefully designed honeycomb endplate design reduces the risk of subsidence, while allowing fusion.

Recombinant Technologies is Raising Capital to Roll Out a Game Changing Alzheimer’s Treatment

Recombinant Technologies is focused on treating the root cause of Alzheimer's Disease delivering a huge improvement in the quality of life of those afflicted.

Tyber Medical Reaches Agreement to Acquire CatapultMD

Once the acquisition is complete, Tyber Medical will own and operate a combined 100,000-square feet of manufacturing space between its Pennsylvania headquarters and Florida-based facilities.

Kleiner Device Labs Receives FDA Market Clearance for KG2 Surge Flow-Thru Interbody System

The system maximizes total bone graft delivery volume, better distributes graft bilaterally into the intervertebral disc space, and streamlines the implant delivery, positioning, and grafting process for TLIF and PLIF spinal fusion procedures.

Matthew Cranfill New ExtriCARE USA Director Of Clinical Services

"Matt's impressive experience and skillset easily made him our top pick," said Peter Mason, President of ExtriCARE USA.

FDA Authorizes Software that Can Help Identify Prostate Cancer

The software is called Paige Prostate and is compatible for use with slide images that have been digitized using a scanner.

By using this website you agree to accept Medical Device News Magazine Privacy Policy